SCHEMBL23218248

SCHEMBL23218248

CCOC(=O)Cc1ccccc1OCc1cc(Br)c2oc(CCO)cc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFD P00746 9/20 0.40
TBXAS1 P24557 1/20 0.40
PRMT5 O14744 1/20 0.36
PTGER1 P34995 1/20 0.36
PTGER4 P35408 1/20 0.36
PTGER3 P43115 1/20 0.36
PTGER2 P43116 1/20 0.36
TPSB2 P20231 3/20 0.35
F11 P03951 2/20 0.35
THRA P10827 1/20 0.35
THRB P10828 1/20 0.35
PLG P00747 1/20 0.35
PLAU P00749 1/20 0.35
KLKB1 P03952 1/20 0.35
F7 P08709 1/20 0.35
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
CYP4F2 P78329 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853076 1.00 CFD (0.40) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL29853099 0.94 TBXAS1 (0.43) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL25881261 0.94 CFD (0.41) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL23218765 0.94 TBXAS1 (0.43) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL21437875 0.90 CFD (0.41) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL21437899 0.89 TBXAS1 (0.40) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL21437602 0.88 TBXAS1 (0.43) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL21438073 0.86 TBXAS1 (0.40) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL29852799 0.86 TBXAS1 (0.40) CFDTBXAS1PRMT5PTGER1PTGER4
SCHEMBL21437433 0.86 CFD (0.42) CFDTBXAS1PRMT5PTGER1PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CFD 1/4885TBXAS1 963/4885PRMT5 4504/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CFD 1/4885TBXAS1 392/4885PRMT5 4233/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.